Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shRNA-DDIT4 refers to short hairpin RNA (shRNA) constructs designed to silence the expression of the DNA Damage Inducible Transcript 4 (DDIT4) gene, also known as REDD1 (Regulated in Development and DNA Damage Response 1). DDIT4 is a potent negative regulator of the mechanistic target of rapamycin complex 1 (mTORC1) pathway, typically induced under stress conditions such as hypoxia, oxidative stress, or DNA damage. By utilizing RNA interference (RNAi) to degrade DDIT4 mRNA, these shRNA molecules effectively disinhibit mTORC1 signaling. This mechanism is of significant therapeutic interest for conditions characterized by pathological mTORC1 suppression, including neurodegenerative diseases like Parkinson's disease, skeletal muscle atrophy, and certain retinal disorders such as diabetic retinopathy and age-related macular degeneration. While primarily utilized as a research tool to investigate cellular stress responses and mTOR regulation, shRNA-DDIT4 constructs are explored in preclinical models as potential gene therapy candidates for neuroprotection and tissue regeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shRNA-DDIT4.